Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

1992

Update on Anxiolytics and Hypnotics
Lynn Osako
University of California, San Francisco

Mary Gutierrez
Chapman University, mgutierr@chapman.edu

Michael Z. Wincor
University of Southern California

Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Recommended Citation
Osako L, Gutierrez MA, Wincor M. Update on anxiolytics and hypnotics. Calif Pharmacist. 1992:32-37.

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.

Update on Anxiolytics and Hypnotics
Comments

This article was originally published in California Pharmacist in 1992.
Copyright

California Pharmacists Association

This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/488

JOURNAL CE------------------------------------------~

•

Lynn Osako, Pharm.D,
Mary Gutierrez, Pharm.D. and
Michael Wincor, Pharm.D.

Update on
anxiolytics and
hypnotics
Goal
The goal of this article is to educate pharmacists on the new er anxiolytic
and hypnotic agents.

Objectives
After reading this article, the pharmacist shouid be able to:
• Discuss the advantages of the new hypnotics and anxiolytics over
previous agents.
• Discuss possible adverse effects and drug interactions of the new
hypnotics and anxiolytics.
• Recommend one of the newer agents as an alternative to more conventionai therapy when appropriate.

Provided by an educational grant from

History
Agents to produce sleep, called
hypnotics, have been around thousands
of yeats. Evidence shows that poppy
plants were used as the first hypnotics
sorne two-thousand yeats ago. The oldest hypnotic agent is chloral hydrate. Its
popularity waned when the barbiturates
came along but has become more popular in the last few decades. 1 It is less
effective than flurazepam and tolerance
toits effects develops rapidly. 2
The bromides were introduced in the
mid-1800s. Problems with these agents
include the ir extremely long half-life of
about 12 days, their low therapeutic index and irritation to the Gl system. 1
Early in the 20th century, barbiturates were introduced and quickly became popular hypnotic agents. These
agents have numerous adverse reactions
such as respiratory depression, nausea
and vomiting, circulatory collapse and
severe depression of the CNS. Barbiturates have become associa red with abuse
and overdose, and drug withdrawal can
also be a serious problem. A chronic user
of barbiturates, upon withdrawal, may
experience irritability, insomnia and, in
serious cases, convulsions and death. 1
Other nonbarbiturate-nonbenzodiazepines indude piperidinediones such
as glutethimide and methyprylon,
ethchlorvynol, methaqualone and meprobamate. Ali of these agents have problems similar to th ose of the barbiturates,
specifically physical dependence and
overdose potential. 1•3
Benzodiazepines were a major breakthrough in sedative-hypnotics and have
become the most frequently prescribed
drugs in the U.S. Their main advantage
over previous agents are their higher
therapeutic index. T aken alone, these
agents rarely cause death and produce
little respiratory depression. 1•3 Physical
dependence has become their major
problem, however. 1
Drug therapies of anxiety states are a
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fairly recent development. Although
anxiety states were recognized in the
19th cenrury, most therapy revolved
around psychotherapy. 4 A variety of
drugs in different pharmacological classes
are now used to treat the anxiety disorders. Alcohol is commonly used to selfrreat situational anxiety; however, it is
never a treatment of choice, 5 and alcoholism has become a complication of
many anxiety disorders. z
When barbiturates came along, they
were not only used as hypnotics, but also
used to treat anxiety. 2 Barbiturates are
not, however, specifie anxiolytics and
have the disadvantages discussed earHer.
Antihistamines are used occasionally
and are especially good for patients with
a high propensity for drug abuse. 5•6 The
anticholinergic effects of these agents
are their primary disadvantage, espe·
cîally in the elderly in whom central
effects such as confusion and hallucinations may also occur.5
Beta-adrenergic blocking agents are
used primarily to alleviate the physical
symptoms of stress. These agents are
nonspecific and rarely are helpful in
psychiatrie patients. 4 Clonidine is also
used to treat anxiety; however, its side
effects of hypotension, depression and
fatigue have limited its use. 5
Antipsychotics were used more frequently for anxiety attacks in the past.
They are less commonly used for thar
purpose now because of their questionable efficacy and the ir high potential for
adverse effects such as tardive dyskinesia
and extrapyramidal effects. 4•6
Antidepressants, however, continue
to be used and have shawn efficacy in
certain anxiety states. In the early 1960s
monamine oxidase inhibitors (MAOls)
were found to be effective for panic
disorder. 6 Phenelzine is most commonly
used, and studies have proven its effectiveness in panic disorder. 5 Side effects
include orthostatic hypotension, weight
gain, sexual dysfunction, edema and

hypertensive crisis, which can occur
when the patient on an MAOI eats food
rich in tyramine (aged cheese, red wine,
sherry, beer, smoked meats orfish, etc.)
and uses sympathomimetics or stimulants. Another disadvantage is that it
takes weeks for a noticeable effect to
occur. 5
lmipramine is the tricyclic amidepressant (TCA) most commonly used
for treating panic disorder, while other
TCAs such as desipramine are occasionally used. 5 Like the MAOis, weeks of
therapy are required before a response
occurs. Their anticholinergic side effects are more pronounced than with the
MAOls and may cause psychotic reactions, especially in the elderly. 2•5 TCAs
can also cause orthostatic hypotension,
tachycardia and decreased cardiac conduction. 2•5 T oxicity is another serious
problem with these patients, and a few
week's supply can easily cause death.
Benzodiazepines, as mentioned carlier, are the most commonly prescribed
drugs in the U.S. Anxiery syndromes
make up a large percentage of those
prescriptions, and benzodiazepines can
be used in ali different types of anxiety
disorders. Their advantages and disadvantages are mentioned above in the
discussion on hypnotics.

The need for newer agents
Although the above-mentioned
agents are effective against anxiety and
insomnia, each has its own problems.
The major disadvantage for all the
hypnotics and for most of the anxiolytics
is their potential for physical dependence. For those anxiolytics without
addictive potential, the primary problems are adverse effects and toxicity.
Therefore, the search goes on for drugs
with specifie actions, few side effects, a
high therapeutic index and no addictive
potential.

Buspirone (Buspar®)
Buspirone is a relatively new drug
which is unique from the beruodiaz-

epines in itschemical and pharmacologie
properties. It was first introduced in 1985
in West Germany and is the first drug
developed primarily as an anxiolytic. 4
Pharmacology. Unlike the benzodiazepines, buspirone actually increases
noradrenergic activity. Buspirone's
mechanism of action is not completely
understood, but it apparently does not
involve action on the benzodiazepinegamma aminobutyric acid-chloride ( BZGABA-Cl) ionophore camp lex. It binds
selectively ta 5-HT lA receptors, and this
is most likely where the majority of its

•
The major
disadvantage for ali
the hypnotics and for
most of the anxiolytics
is their potential for
physical dependence.
For those anxiolytics
without addictive
potential, the primary
problems are adverse
effects and toxicity.

anxiolytic activity is produced. 7 These
receptors are localized in areas of the
CNS which may explain its more favorable adverse effect profile versus the
benzodiazepines. Buspirone does not
share the anticonvulsant and muscle
relaxant properties of the benzodiazepines and exhibits anxiolytic effects
only.7
Pharmacokinetics. Buspirone is absorbed rapidly and completely from the
01 system. After undergoing first-pass
metabolism only 4% of the drug reaches
the systemic circulation.5 The onset of
action of buspirone is considerably de-
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layed and occurs sometime during the
first three weeks of therapy; therefore, it
cannat be used for short-term or asneeded treatment. The distribution of
buspirone is not completely known. The
apparent volume of distribution is about
5.3 L/kgJ It is 95% bound to plasma
proteins, 5 mostly to albumin and a 1acid glycoprotein. The elimination halflife is about four hours in healthy patients while it is prolonged with renal
impairment and hepatic cirrhosis.
Buspirone is metabolized in the liver,
primarily by oxidation, into several metabolites. The major active metabolite is
1-pyrimidinyl-piperazine (1-PP). lt has
about 20-25% of the anxiolytic activity
ofbuspirone; 7 however, it is unclear how
much it adds to buspirone's action. Both
buspirone and its metabolites are excreted primarily in the urine although
less than 0.1% is excreted as unchanged
drug. 7

should be a 10-day washout after MA01
use before buspirone therapy is initiated. 8 The re have been reports of elevations in ALT concentrations with concomitant buspirone and trazodone use.
However, this remains unconfirmed in
studies. As long as liver function tests
are monitored, the manufacturer daims
thar the two may be used together. 8
When haloperidol and buspirone are
used together, elevations occur in
haloperidol concentration. This probably occurs through competition resulring in the inhibition of the metabolism
of haloperidol. 8 lt is not recommended
that both be used concurrently until
more information is obtained on this
interaction. 8 Buspirone does not appear
to interact with benzodiazepines; however, it is still recommended that they
not be given together. 8
Indications. Indications for buspirone
include generalized anxiety disorders.

Adverse effects. Adverse effects
which have been reported include gastrointestinal complaints (nausea and
vomi ting), dizziness and headache. Each
of rhese side effects were reported in less
than 10% of patients. Sedation is reported in 10% of patients, which is the
same incidence as with placebo. There
are slightly more reports of adverse effects in the elderly. 4 Also, there are few
reports of psychomotor impairment.
Another unique feature of buspirone is
its inability to potentiate the effect of
alcohol and lack of addiction potential. 4
There is little information on the
toxicity ofbuspirone. Because dysphoria
may occur at higher doses of 20-40 mg, 7
there is low potential for abuse. There
also is little evidence rhat withdrawal
occurs with sudden discontinuation of
the drug. For acute roxicity, there are no
specifie antidotes and treatment usually
involvessupportive care. The lethal dose
in humans is unknown. 4
Drug interactions. Drug interactions
include elevated blood pressure in patients with concurrent MAOI use.
Therefore, ir is not recommended to
give both concomitantly, and there

•

The side effect profile
of buspirone is a
definite advantage
overthe
benzodiazepines.
There is little
sedation, making it
an alternative for
patients in whom the
sedation and
psychomotor
impairment are
intolerable.

Studies have shown that buspirone is as
effective as benzodiazepines for these
disorders. 8 In severe anxiety, however,
buspirone is lesseffective than lorazepam
and diazepam. 5 Previous treatment with
benzodiazepines is often associated with
disappointment in buspirone therapy. s, 7
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This is probably due to its long onset of
action and because buspirone does not
alleviate the withdrawal symptoms of
benzodiazepines.
Dosing and administration.
Buspirone is only available orally. The
starting dose is 10-15 mg/cl in two or
three divided doses. lt can be given with
or without food. Increases of 5 mg/day
every two to four days can be made after
one week of therapy at 15 mg/day. The
usual maximum dose is 60 mg/day. Optimal effects may not occur for as long as
six weeks. 5 It has not been determined
how to ad just doses in hepatic and renal
impairment. Sorne have suggested a 2550% reduction in patients thatare anurie.
The side effect profile ofbuspirone is
a defini te advantage over the benzodiazepines. There îs little sedation, making
it an alternative for patients in whom
the sedation and psychomotor impairment are intolerable. lt would also be
indicated in patients who may have a
history of drug dependence. The disadvantage is its long onset of action. ln
patients with symptoms requiring immediate alleviation, buspirone may not
be ideaL

Clomipramine (Anafranil®)
Clomipramine is a tricyclic antidepressant used for more than 20 years in
Europe and Canada which has more
recently been used for various anxiety
disorders. 9 lt is so far the only agent
approved for obsessive-compulsive disarder (OCD) and is marketed in the
U.S. for this indication.
Pharmacology. Clomipramine inhibits reuptake of serotonin and norepinephrine like the other tricyclic amidepressants and is the most potent serotonin reuptake blocker in its class. 10 The
activity of clomipramine is thought to
be due toits inhibitory effect on serotonin. This activity increases serotonin
levels, and long-term treatment may lead
to a clown regulation of the serotonin
receptors. However, its exact mechanism is unknown. 9 •10
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Pharmacokinetics. Absorption is
rapid and complete from the Gl system,
but the drug undergoes first pass effect.
Systemic bioavailability is about 50%. 11
The distribution pattern has yet to be
completely determined. The mean apparent volume of distribution is
12 L/kg. 11 lt is 98% protein bound to
plasma proteins.9· 11 Clomipramine isextensively metabolized to a variety of
metabolites. Demethylclomipramine,
the major metabolite and a result of first
pass demethylation, is active. Approximately 50-60% of the oral dose is found
in the urine and the rest is in the feces.
The mean elimination half-life of
clomipramine is 32 hours while
demethylclomipramine's mean half-life
is 69 hoursP
Adverse effects. Clomipramine has
the same adverse effect profile as the
other tricyclic antidepressants. 9 The
anticholinergic effects are most promi-

FSI

nent and include dry mouth, constipation, sweating, blurred vision and urinary retention. 9 Cardiac effects include
orthostatic hypotension, syncope, palpitations and tachycardia. 9 Seizures have
been reported at an incidence of 0.7%
and were more common with high doses
( >300 mg/day) and with intravenous
administration. 9 One particularly disturbing problem to patients is sexual
dysfunction, although normal function
retums withdiscontinuation of the drug. 9
Weight gain can also be a problemY lt is
essential to counsel patients about these
two side effects. ln sorne trials there is a
dropout rate of up to 28%. 9
Acute toxicity with clomipramine is
similar to those of other tricyclic amidepressants. Symptoms include severe anticholinergic effects. ln extreme cases,
hypotension, coma, cardiac abnormalities, convulsions and respiratory arrest
may occur. T rearment involves the usual

treatment of trieyclic antidepressant toxicity. The guidelines can change; therefore, a poison center should be ca lied for
updated information. 12
Indications. Clomipramine, unlike
most of the other tricyclic antidepressants, is used to treat obsessive compulsive disorder and panic disorder. Early
studies have shown thar clomipramine
is superior to other tricyclic antidepressants in treating OCD. 9•10
Dosing and administration. The starting dose for domipramine in OCD is 25
mg two to three times daily. 10 The dose
should be increased slowly depending
on response and tolerance of side effects,
up to 100-150 mg, although 250 mg has
been used. Drug effect can take as long as
five to six weeks to manifestY Once
symptoms have been alleviated the dose
should be brought down to the lowest
effective level.
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Quazepam (Dorai@)

Quazepam is a benzodiazepine introduced in 1990. The action of quazepam,
like other benzodiazepines, revolves
around its actions on GA BA. Quazepam
and one of its metabolites, 2oxoquazepam (OQ), have selectivity for
type 1 benzodiazepine receptors. 13 This
is a unique quality which is shared by
only one ether benzodiazepine,
halazepam. The significance of this selectivity is yet to be elucidated. 14
Phannaeokinetics. Quazepam is absorbed rapidly and its bioavailability is
approxima tely 80%. 8 There is, however,
extensive first pass metabolism in animals which has not been quantified in
humans. Quazepam is distributed into
most tissues and body fluids, and the
apparent volume of distribution is 5 L/kg
when given at bedtime and 8.6 L/kg
when given in the moming. 14 Both
quazepam and OQ distribute quickly
into the CNS and are more than 95%
bound to plasma proteins. 13 Quazepam
is extensivelymetabolized toOQ and Ndesalkyl-2-oxoquazepam (DOQ), which
is identical to N-desalkylflurazepam.
Both metabolites have similar activity
to the parent drug. The half-life of
quazepam and OQ is about 40 hours.U' 14
The half-life of DOQ is about 70-75
hours. 13 In the elderly, the most significantchange in half-life is in DOQ, which
can increase to 190 hours.l 4 Both metabolites are metabolized ultimately via
conjugation with glucuronide formation.
Quazepam is excreted both in urine and
feces with very little in its original form.
Adverse effects. Adverse effects of
quazepam are similar to other benzodiazepines. These indude CNS depression
and physical dependence. Quazepam
may cause more daytime sedation than
other benzodiazepines with shorter halflifes. Sedation is also more of a problem
at the higher dose of 30 mg. 13 Side effects are usuaUy most pronounced in the
first few days and may diminish with
ti me or with decreases in dosage. At one
week and four weeks of therapy, there
appears to be little daytime drowsiness. 15

There have been rare reports of confusion and psychotic-like symptoms at the
30 mg dose, but none are reported at the
15 mg dose. 14 Rebound insomnia is not
a problem with quazepam due to the
long half-life ofDOQ.D With respect to

•
When compared with
temazepam,
quazepam appears to
be more effective
with short-term use,
and there also seems
to be less tolerance
development when
quazepam is used
longer term.

dependence, quazepam appears to have
a low potential for abuse due to its
carryover effects and decreased incidence
ofrebound insomnia. No definitive statements can be made though untillarger
numbers of patients use this drug and
more studies are done. 14
Drug interactions. Drug interactions
include additive CNS effects with other
CNS depressants, anticonvulsants and
alcohol. If drugs from both classes need
to be used together, reductions in doses
will be required to prevent overdosage.
Administration ofdisulfiram and benzodiazepines which undergo oxidative
merabolism may result in a decreased
metabolism of the benzodiazepine. 8
Since quazepam is one of the these agents,
patients taking both these agents should
be watched for a greater response to
quazepam. This is also the case with
concomitant cimetidine administration.
Cimetidine may inhibit the clearance of
quazepam; therefore, response must again
be monitored and dosage reductions

J6 • CALIFORNIA PHARMACIST • NOVEMBER 1992

made as necessary. 8
Indications. Quazepam is used primarily as a hypnotic. lt shares a similar
pharmacokinetic profile as flurazepam
and is very comparable in terms of efficacy and side effect profile. Flurazepam
may have better long-term effectiveness, however. 14 When compared with
temazepam, quazepam appears to be more
effective with short-term use, and there
also seems to be less tolerance development when quazepam is used longer
term. 13 •14
Dosing and administration.
Quazepam is available in oral form and
given only a bedtime. The starting dose
is 15 mg in most adults. ln sorne people,
7.5 mg may be enough. The higher dose
of 30 mg is sometimes used, but there is
generally more daytime sedation at that
dose. Quazepam and flurazepam share
the same active metabolite and will
therefore share many of the same properties. Quazepam may have advantages
over temazepam and triazolam, but seerns
to have little over flurazepam.
Estazolam (ProSom®)

lntroduced in 1991, Estazolam is another new benzodiazepine.
Pharmacology. Like other benzodiazepines, estazolam's actions are due to
its effects on GABA. It is unknown
whether estazolam has selectivity for
either benzodiazepine type 1 or 2 receptors.
Pharmacokinetics. Estazolam is both
rapidly and well-absorbed from the GI
tract. The bioavailability is approximately 98%. It distributes widely into
most tissues and fluids, and it appears to
cross the blood-brain barrier.8 The halflife ranges from 8-31 hours. 2 Estazolam is
metabolized hepatically, and its metabolites have little activity. The two principal ones are 4-hydroxyestazolam and 1oxo-estazolam. Both estazolam and its
metabolites are primarily excreted in
urine with a small percent excreted in
feces.

'
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Adverse effects. The side effect profile is essentially the same as that for
quazepam, as is the drug interaction profile. In a study looking at long-term
administration, no tolerance was seen
during the six weeks of therapy. 16 The
same study showed that rebound insomnia could occur with sudden withdrawal,
but that this was just temporary. 16
Drug interactions. Estazolam is oxidatively metabolized; therefore, there is
again the potential for its increased activity when given with cimetidine or
disulfiram. Doses should be adjusted
when given concomitantly with these
agents.
Indications. Estazolam is used, as are
other benzodiazepines, as a hypnotic.
Estazolam has an intermediate half-life
which makes it less likely to cause daytime sedation than th ose with long halflives. It is also less likely to cause the
rebound insomnia seen when discontinuing benzodiazepines with short ha Iflives. Early studies show that estazolam
has fewer side effects than flurazepam
and is equally efficacious as a hypnotic. 17

nificant advantage over previous agents.
Buspirone appears to be a breakthrough
in rhat it is significantly different from
previous agents. It has specifie effects,
low incidence of side effects and little, if
any, addiction potential. However, its
long onset of action is a disadvantage.
Clomipramine also has sorne advantages
in that it has increased efficacy over
imipramine in the treatment of OCD;
however, it has many of the same side
effects. The two newer benzodiazepines
appear to have little advantage over the
older agents. Perhaps with continued
use, more advantages and/or disadvantages will be revealed. It appears that the
search for the perfect anxiolytic and
hypnotic will have to continue.
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